1 / 46

Safety and Security Requirements for Select Agent Research

Safety and Security Requirements for Select Agent Research. Bioterrorism. Definitions. Biological terrorism (BT) – Use of biological agent on a population to deter, hinder, or otherwise slow the productivity of a community.

thuyet
Download Presentation

Safety and Security Requirements for Select Agent Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Safety and Security Requirements for Select Agent Research

  2. Bioterrorism

  3. Definitions • Biological terrorism (BT) – Use of biological agent on a population to deter, hinder, or otherwise slow the productivity of a community. • Biological warfare (BW) -Use of biological agent to harm or kill an adversary’s military forces, population, food, and livestock. • Select agents (SA): designated subset of biological agents or toxins identified as having the potential to be used in weapons of mass destruction (WMD’s)

  4. Types of Biological Weapons • Bacterial agents • Viral agents • Biological toxins

  5. Advantages of BT • Killing efficacy • Cost effectiveness • Vehicle • Relative ease of production • Interval between dissemination to infection

  6. History • Ancient – 20th century • 20th century – 1972 • 1972 – today

  7. Does the Siege at Caffa Correlate with the Initiation of Black Death? 1346 - 1352

  8. 20th Century to 1972 • World War I • Glanders and anthrax used on horses • Geneva Protocol (1925) • 40 violations from 1969-86 of prohibitions of bioweapons used in war • World War II - Unit 731, Manchuria, China – weapons tests on Chinese

  9. 20th Century to 1972 • US military bio-weapon program, 1950-72 • Ft. Detrick, Maryland • Pine Bluff Arsenal, Arkansas • 1966, B. subtilis in NYC subway - Study dissemination patterns • 1969, Serratia in San Francisco - Study line-source dissemination • Biological Weapons Convention, 1972 • Today, 148 signatories - India, North Korea, Pakistan, Iran among those not signed

  10. 1972 - Today • 1979, Sverdlovsk, Russia • 66 fatalities from anthrax release • For 13 years USSR government tells public it was due to ingestion of contaminated meat. • 1992, Boris Yeltsin admits a faulty HEPA exhaust filter as the result of the release from Building 19. • Science, 1994, 266(5188):1202-8.

  11. 1972 - Today • 1992, Aum Shinrikyo cult • Weaponize anthrax • - 10 botched attempts (1992) • Travel to Zaire to find Ebola • Sarin gas attacks in Japan

  12. Where in the World is Safety Bob and what is the public health significance of this place?

  13. The former Shakey’s Pizza where the Bhagwan Shree Rajneesh cult conducted the first known bio agent attack in the US in September 1984, spraying salmonella on the salad bar to in an attempt to prevent citizens from voting in an upcoming election

  14. The 2001 Anthrax Letters • 23 reported cases of anthrax • New York City (8), New Jersey (7), D.C. (5), Florida (2), and Connecticut (1) • 11 inhalation anthrax (5 deaths) • 12 cutaneous anthrax • 9/11 inhalation anthrax cases are linked to direct exposure to contaminated mail • 2 cases had no known exposure (61 y.o. woman in NY, 94 y.o. woman in CT)

  15. Anthrax • Bacillus anthracis • Gram (+) sporulating rod • 3 antigens formed • (EF), (LF), (PA) • Presence of (LF) and (PA) = pathogenic • 3 distinct clinical syndromes • Cutaneous • Inhalational • Gastrointestinal

  16. Inhalational Anthrax • Infective Dose = 8,000 - 15,000 spores • Incubation period = 1-6 days • Duration of illness = 3-5 days • Diagnostic Hallmark • Widened mediastinum • Treatment: • Ciprofloxacin: 500mg bid x 4 wk • Doxycycline: 100mg bid x 4 wk

  17. Anthrax - Clinical Presentations

  18. October 2001: Anthrax Mail Attacks:UTHSC-H Experience

  19. Ricin • Derivative from castor bean plant, Ricinus communis • Protein cytotoxin that inhibits protein synthesis through its 2 polypeptide chains • Marginal toxicity when compared to other biological toxins • LD50 = 30 μg/kg • Recent history • 1978 – Bulgarian dissident • 1996 – KC Oncologist intent to use • 1997 – WI resident possession • 2003 – Al Qaeda plot • 2004 – Washington DC letter

  20. Ricin, cont’d Major clinical presentations: • Inhalation • Rapid onset (4-8 h) – fever, chest tightness, cough, dyspnea, nausea • Respiratory failure (36-72 h) and pulmonary edema • Injection • Same onset as inhalation • Local lymphoidal and muscle necrosis, GI hemorrhaging • Ingestion • Less toxic than above • Onset of symptoms similar time – abdominal pain, vomiting, diarrhea, progressing to GI hemorrhaging, hepatic, splenic, and renal necrosis • Death 3-5 days – cessation of circulatory system

  21. Smallpox • Variola major virus • Orthopox virus • BW threat from aerosolization • Acute stages often confused with Varicella (chickenpox) • Differentiation: • Smallpox typically evolves distally • Lesions generally all is same stage • Febrile illness prodromal stage • Eradicated by WHO in 1980 • US & UN delay destruction of reserves until 7-02 • Delayed longer • Treatment • No known cure • Vaccinia Immune globulin • Cidofovir

  22. Smallpox Presentation

  23. Given the Threat – What to Do? • Preparedness Needs • Detection - Health Surveillance • Rapid Laboratory Diagnosis • Epidemiological Investigations • Implementation of Public Health Control Measures • Communication network • Research and Development • PPE, respirators • Triage and decontamination methods • Vaccines, prophylaxis

  24. Web Resources • www.bt.cdc.gov • http://www.osha.gov/SLTC/biologicalagents/index.html • http://www.usps.com/news/2001/press/pr01_1010tips.htm • http://www.texasbiosecurity.org/ • www.aphl.org • www.defenseofhouston.org • http://www.cdc.gov/od/sap/

  25. The Select Agent Rule

  26. Foundation for Select Agents • Antiterrorism and Effective Death Penalty Act of 1996 (PL 104-132) • Invoke transport requirements, and prohibited possession as weapons • USA PATRIOT Act (PL 107-56) • Effective 10/16/01 • Controlled the possession of 49 Select Agents/Toxins for any use: peaceful, research, or intentional • Outlawed use if a “restricted person”

  27. Public Health Security and Bioterrorism Preparedness and Response Act of 2002 • (PL 107-188) effective 6/12/02 • Covers both human and plant/animal select agents; joint program between HHS (CDC) and USDA (APHIS) • 9/10/02 - CDC notification of possession or use of SA by facilities required; negative certification also required • 12/12/02 – Interim final rule published • 02/14/03 – Interim final rule enacted as law • 03/18/05 – Final Rule released

  28. What is a Select Agent? • List of agents can be found on the CDC and APHIS websites http://www.cdc.gov/od/sap/docs/salist.pdf • Includes infectious agents and biological toxins of WMD concern; often termed “dual use” • There are some exemptions for certain strains and amounts of toxin per PI

  29. 42 CFR 73 – Select Agent Regulations • 73.7 Registration & related security risk assessment • 73.9 Responsible Official • 73.10 Restricting access to Select Agents • 73.11 Security plan • 73.12 Biosafety plan • 73.14 Incident Response • 73.15 Training • 73.18 Inspections • 73.19 Notification for Theft, Loss, or Release

  30. CFR 73.7 - Registration • You must be registered prior to beginning work • Registration good for 3 years • Facility must meet CDC/NIH BMBL guidelines in addition to security requirements

  31. CFR 73.7 – Related Security Risk Assessment • Registration information required to be submitted so that Attorney General may perform risk assessment of work at institution with Select Agents

  32. CFR 73.9 – Responsible Official • Responsible Official (RO) and an Alternate Responsible Official (ARO) must be designated • This individual must have resources available to ensure compliance

  33. CFR 73.10 – Restricting Access • Must be an authorized person to have unrestricted, unsupervised access to Select Agents -training & experience required -must be approved by Attorney General • Authorization granted for a period of five years

  34. Statement of Eligibility • Denied SA possession if ‘Yes’ to any of following: • Jail >1 year • Fugitive from justice • Controlled substance use • Citizen of one of UN recognized terrorist countries • Committed to a mental institution • Dishonorably discharged

  35. CFR 73.11 – Security • Inventory Control Measures • Physical Security - Looking for at least 3 levels • Cyber Security • Provisions for visitors, housekeeping, and maintenance • Procedures for lost passwords, keys, IDs, personnel leaving, unauthorized personnel

  36. CFR 73.12 - Biosafety Plan • Biosafety and containment procedures set forth following BMBL and NIH rDNA Guidelines • i.e. entry protocols; PPE; general and special practices and procedures • Plan must be tested at least annually using drills to evaluate the effectiveness of plan or after any incident

  37. CFR 73.14 - Incident Response • Do you have an institutional Emergency Situations Response Plan (ESRP)? Where is it located? • Planning and coordination with outside parties • What are the emergency hazards associated with select agent? • Oral, Contact (dermal), Inhalational hazards • What are the hazards associated with response that could lead to the spread of select agent? • Do you have appropriate site security and control during emergency? • Where do you find information about the specific hazards associated with the select agent? • Biosafety Plan

  38. CFR 73.15 - Records • Current, accurate list of individuals approved for access to select agent • Current, accurate inventory of select agent • Name, characteristics, and source data • Quantity acquired and date of acquisition • Quantity destroyed and date of destruction • Quantity transferred, date of transfer, and to whom it was transferred (EA-101) • Records of APHIS/CDC Form 2 (EA-101) transfers • Access to area where select agent is used or stored

  39. CFR 73.19 – Notification for Theft, Loss, or Release • Must have a procedure for any of the above events • Must complete report to USDA or CDC using APHIS/CDC Form 3

  40. Penalties • 42 CFR 1003 imposes strict penalties for violations of 42 CFR Part 73 • Imprisonment of up to 5 years • “….. $250,000 in the case of an individual” • “……$500,000 in the case of any other person” • Failure to completely comply also carries significant reputational risk

  41. Foreseeable Trends • Increasing regulatory requirements, inspections, scrutiny • Opportunities for research • The FY03 budget for Department of Homeland Security was $37,450,000,000

  42. Commentary • Additional bureaucratic controls for select agents are imminent • These rules will not always be based on sound science • Incompatibilities with universities: • Designed as traditionally open environments • Internationally diverse populations • Population eschews being told what to do • Openly shares information • But the work is important –so an infrastructure is needed to support this type of activity

  43. Commentary (con’t) • When looking at positions, suggest asking about the support infrastructure in place - specifically: Who does EH&S report to? Who is the designated “responsible official”? Is “select agent” work currently underway? What facilities exist and are planned?

  44. Summary • Biosafety is much more than just research protocol reviews or bloodborne pathogens • Risk assessment process the key to properly classifying and reviewing research with infectious agents or rDNA • Safety department must rely on the expertise of the committee for assistance • Select agent work is highly regulated and scrutinized

  45. References • 42 CFR 73 (CDC) http://www.cdc.gov/od/sap/42_cfr_73_final_rule.pdf • 7 CFR 331 and 9 CFR 121 (APHIS) http://a257.g.akamaitech.net/7/257/2422/01jan20051800/edocket.access.gpo.gov/2005/pdf/05-5063.pdf • Biosafety in Microbiological and Biomedical Laboratories, 4th ed. CDC/NIH 1999 • Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) April 2002 • Health Canada MSDS for Biological Agents • http://www.phac-aspc.gc.ca/msds-ftss/index.html#menu?

More Related